TABLE 3.
Top 20 validated PD pattern metabolites in fully adjusted models in the WHI-HT1
| βWD (SE) | Regression coefficient, βPD continuous 1 SD (SE) | P | ||||||
|---|---|---|---|---|---|---|---|---|
| Metabolite | HMDB ID | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | Continuous | FDR continuous | |
| C22:6 LPC | HMDB10404 | Reference | 0.19 (0.08) | 0.35 (0.08) | 0.50 (0.08) | 0.18 (0.03) | 7.88 × 10−9 | 7.02 × 10−7 |
| C38:6 PC | HMDB07991 | Reference | 0.17 (0.08) | 0.33 (0.08) | 0.46 (0.08) | 0.18 (0.03) | 1.20 × 10−8 | 7.02 × 10−7 |
| C20:5 CE | HMDB06731 | Reference | 0.13 (0.08) | 0.26 (0.08) | 0.40 (0.08) | 0.17 (0.03) | 2.53 × 10−8 | 9.85 × 10−7 |
| C58:8 TAG | HMDB05413 | Reference | 0.14 (0.08) | 0.16 (0.08) | 0.38 (0.08) | 0.17 (0.03) | 8.48 × 10−8 | 1.98 × 10−6 |
| Uridine | Uridine | Reference | 0.13 (0.08) | 0.25 (0.08) | 0.42 (0.09) | 0.17 (0.03) | 8.42 × 10−8 | 1.98 × 10−6 |
| C60:12 TAG | HMDB05478 | Reference | 0.12 (0.08) | 0.14 (0.08) | 0.39 (0.08) | 0.16 (0.03) | 1.13 × 10−7 | 2.20 × 10−6 |
| C22:6 CE | HMDB06733 | Reference | 0.16 (0.07) | 0.26 (0.08) | 0.40 (0.08) | 0.15 (0.03) | 1.53 × 10−7 | 2.24 × 10−6 |
| C58:9 TAG | HMDB05463 | Reference | 0.15 (0.08) | 0.18 (0.08) | 0.39 (0.08) | 0.16 (0.03) | 1.39 × 10−7 | 2.24 × 10−6 |
| C40:10 PC | HMDB08511 | Reference | 0.19 (0.08) | 0.30 (0.08) | 0.43 (0.08) | 0.16 (0.03) | 2.05 × 10−7 | 2.66 × 10−6 |
| Eicosapentaenoate | HMDB01999 | Reference | 0.15 (0.08) | 0.25 (0.08) | 0.39 (0.08) | 0.16 (0.03) | 2.98 × 10−7 | 3.19 × 10−6 |
| C58:11 TAG | HMDB10531 | Reference | 0.15 (0.08) | 0.14 (0.08) | 0.38 (0.08) | 0.16 (0.03) | 3.00 × 10−7 | 3.19 × 10−6 |
| Uracil | Uracil | Reference | 0.08 (0.08) | 0.20 (0.08) | 0.35 (0.09) | 0.16 (0.03) | 3.34 × 10−7 | 3.26 × 10−6 |
| C58:10 TAG | HMDB05476 | Reference | 0.16 (0.08) | 0.16 (0.08) | 0.37 (0.08) | 0.15 (0.03) | 7.31 × 10−7 | 6.58 × 10−6 |
| C22:6 LPE-B | HMDB11526 | Reference | 0.12 (0.08) | 0.30 (0.08) | 0.42 (0.08) | 0.15 (0.03) | 7.95 × 10−7 | 6.65 × 10−6 |
| Indole-3-propionate | Indole-3-propionate | Reference | 0.07 (0.08) | 0.18 (0.08) | 0.42 (0.08) | 0.15 (0.03) | 1.05 × 10−6 | 8.22 × 10−6 |
| C40:6 PC-B | HMDB08057 | Reference | 0.09 (0.08) | 0.29 (0.08) | 0.38 (0.08) | 0.15 (0.03) | 1.25 × 10−6 | 9.16 × 10−6 |
| C56:10 TAG | HMDB10513 | Reference | 0.17 (0.08) | 0.20 (0.08) | 0.37 (0.08) | 0.15 (0.03) | 2.79 × 10−6 | 1.92 × 10−5 |
| DHA | DHA | Reference | 0.15 (0.08) | 0.28 (0.08) | 0.38 (0.08) | 0.14 (0.03) | 4.77 × 10−6 | 2.94 × 10−5 |
| C56:9 TAG | HMDB05448 | Reference | 0.14 (0.08) | 0.16 (0.08) | 0.35 (0.09) | 0.14 (0.03) | 4.76 × 10−6 | 2.94 × 10−5 |
| C56:8 TAG | HMDB05392 | Reference | 0.13 (0.08) | 0.18 (0.08) | 0.35 (0.09) | 0.14 (0.03) | 7.55 × 10−6 | 4.42 × 10−5 |
Single metabolite linear regression models for each metabolite (outcome) with respect to primary exposure of interest, while adjusting for age, BMI, batch, ethnicity, enrollment time, energy intake, exercise, case-control status, smoking (current vs. past/never), income (<
34,999 vs. ≥
34,999), education, and medication use at baseline (aspirin, statin, hypertension medications, diabetes medications). CE, cholesteryl ester; FDR, false discovery rate; HMDB, Human Metabolome Database; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PD, Prudent dietary pattern; TAG, triacylglycerol; WHI-HT, Women's Health Initiative Hormone Therapy Trial.